2 Top Healthcare Stocks Defying the Bear Market
Eli Lilly (NYSE: LLY) and Merck (NYSE: MRK) have seen their shares rise by over 17% and 5%, respectively, this year while the S 500 Health Care Sector Index has dropped 1.7%. What's interesting is that the two pharmaceutical companies' shares are up, despite first-quarter reports that showed both stocks with declining revenue and net income, year over year.
That's because each company has strong potential for long-term growth, thanks to emerging drugs. For Merck, it is a pipeline bolstered by vaccines and oncology therapies. For Lilly, it's a weight-loss drug and an Alzheimer's disease therapy that are showing huge potential.
Eli Lilly's tirzepatide, known as Mounjaro when sold as a Type 2 diabetes therapy, just earned a key trial victory as a weight-loss therapy. In a phase 3 trial, Lilly said the drug helped diabetes patients who were obese or overweight lose up to 15.7% of their body weight. The study included 938 adults and also met all key secondary objectives, including a reduction in A1C and other cariometabolic measures, the company said.
Source Fool.com
Merck KGaA Aktie
3 Buy-Einschätzungen und 4 Sell-Einschätzungen halten sich bei der Aktie die Waage.
Mit einem Kursziel von 135 € für Merck KGaA könnte eine leichte Minderung gegenüber dem aktuellen Kurs von 147.95 € erreicht werden.
